z-logo
open-access-imgOpen Access
The expression and clinical significance of GADD45A in breast cancer patients
Author(s) -
Junnan Wang,
Yiran Wang,
Fei Long,
Fengshang Yan,
Ning Wang,
Yajie Wang
Publication year - 2018
Publication title -
peerj
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.927
H-Index - 70
ISSN - 2167-8359
DOI - 10.7717/peerj.5344
Subject(s) - breast cancer , immunohistochemistry , estrogen receptor , oncology , medicine , cancer , clinical significance , triple negative breast cancer , ki 67 , cancer research , pathology
Background Growth arrest and DNA-damage-inducible protein 45 alpha (GADD45A) was previously found to be associated with risk of several kinds of human tumors. Here, we studied the expression and clinical significance of GADD45A in breast cancer. Methods We performed an immunohistochemical study of GADD45A protein from 419 breast cancer tissues and 116 adjacent non-neoplastic tissues. Results Significantly high GADD45A expression were observed in breast cancer tissues compared with adjacent non-neoplastic tissues ( P  < 0.001) and were independently correlative with estrogen receptor negative ( P  = 0.028) and high Ki-67 index ( P  < 0.001). Kaplan–Meier survival analysis revealed that patients with high GADD45A expression levels had a worse long-term prognosis in triple negative breast cancer ( P  = 0.041), but it was not an independent prognostic factor in multivariate analysis ( P  = 0.058). Conclusions GADD45A expression levels are significantly correlative with estrogen receptor status and Ki-67 index in human breast cancer. Patients with triple negative breast cancer might be stratified into high risk and low risk groups based on the GADD45A expression levels.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom